Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: A STROBE-compliant study

Golimumab is a fully human monoclonal antibody against tumor necrosis factor (TNF) approved for the treatment of ulcerative colitis and not for Crohn disease (CD). Many CD patients experience primary, secondary failure, or intolerance to other TNF inhibitors (TNFi) approved in Italy for CD (adalimum...

Descripción completa

Detalles Bibliográficos
Autores principales: Conigliaro, Paola, Chimenti, Maria Sole, Triggianese, Paola, D’Antonio, Arianna, Sena, Giorgia, Alfieri, Norma, Biancone, Livia, Perricone, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281909/
https://www.ncbi.nlm.nih.gov/pubmed/33761677
http://dx.doi.org/10.1097/MD.0000000000025122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281909/
https://www.ncbi.nlm.nih.gov/pubmed/33761677
http://dx.doi.org/10.1097/MD.0000000000025122

Ejemplares similares